TCM
GTBP icon

Triumph Capital Management’s GT Biopharma GTBP Stock Holding History

Triumph Capital Management’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$810 Hold
66
– – ﹤0.01% 1685
2026
Q1 		$675 Hold
66
– – ﹤0.01% 1672
2025
Q4 		$1.3K Buy
+66
New +$1.17K ﹤0.01% 1534

Other funds holding GTBP

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return
OWA
Opal Wealth Advisors Jericho, New York $463M AUM 20.47% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM

Triumph Capital Management's GTBP Position: Q2 2026 in Review

Triumph Capital Management held its GT Biopharma (GTBP) position steady in Q2 2026 at 66 shares worth $810. The position accounts for ﹤0.01% of the portfolio, ranked #1685.

Triumph Capital Management first reported a position in GTBP in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.3K in Q4 2025. 55 funds tracked by Wall St. Rank hold GTBP as of Q2 2026.

  • Triumph Capital Management held 66 shares of GT Biopharma worth $810 as of Q2 2026.
  • Triumph Capital Management left its GT Biopharma share count unchanged in Q2 2026.
  • GT Biopharma made up ﹤0.01% of Triumph Capital Management's portfolio in Q2 2026, its #1685 holding.
  • Triumph Capital Management first reported a position in GT Biopharma in Q4 2025 and has held it in 3 quarters since.
  • Triumph Capital Management's GT Biopharma position peaked at $1.3K in Q4 2025.
  • 55 funds tracked by Wall St. Rank held GT Biopharma as of Q2 2026.

Based on Triumph Capital Management's 13F filing for Q2 2026, filed 21 Jul 2026.